Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation

BACKGROUND: Poor infiltration and limited activation of transferred T cells are fundamental factors impeding the development of adoptive cell immunotherapy in solid tumors. A tumor-penetrating peptide iRGD has been widely used to deliver drugs deep into tumor tissues. CD3-targeting bispecific antibo...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Immunother Cancer
Egile Nagusiak: Zhou, Shujuan, Meng, Fanyan, Du, Shiyao, Qian, Hanqing, Ding, Naiqing, Sha, Huizi, Zhu, Mei, Yu, Xiaoxiao, Wang, Lifeng, Liu, Baorui, Wei, Jia
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2021
Gaiak:
Immune Cell Therapies and Immune Cell Engineering
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8126316/
https://ncbi.nlm.nih.gov/pubmed/33986122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001925
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak